DUBLIN--(BUSINESS WIRE)--The "Cellular-Mesenchymal Epithelial Transition Factor (C-Met) Mutated Non-small Cell Lung Cancer (NSCLC)- Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the disease, historical and forecasted c-Met Mutated NSCLC epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Total cases of C-Met mutated NSCLC in the 7MM was assessed to be 16,658 in 2017, and are expected to increase during the study period. Among the European 5 countries, the Germany had highest incident population of C-Met NSCLC, followed by United Kingdom and France. On the other hand, Spain had the lowest incident population of C-Met NSCLC, in 2017. Furthermore, Japan accounts for about 12% of the total 7MM incident population of C-Met NSCLC (in 2017).
Key Questions Answered
- What will be the growth opportunities in the 7MM with respect to the patient population pertaining to C-Met mutated NSCLC?
- What are the key findings pertaining to the C-Met mutated NSCLC epidemiology across the 7MM and which country will have the highest number of patients during the study period (2017-2030)?
- What would be the total number of patients of C-Met mutated NSCLC across the 7MM during the study period (2017-2030)?
- Among the EU5 countries, which country will have the highest number of patients during the study period (2017-2030)?
- At what CAGR the patient population is expected to grow in the 7MM during the study period (2017-2030)?
- What are the various recent and upcoming events which are expected to improve the diagnosis of C-Met mutated NSCLC?
Reasons to buy
- Develop business strategies by understanding the trends shaping and driving the global C-Met mutated NSCLC market
- Quantify patient populations in the global C-Met mutated NSCLC market to improve product design, pricing, and launch plans
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for C-Met mutated NSCLC therapeutics in each of the markets covered
- Understand the magnitude of C-Met mutated NSCLC population by its severity
- The C-Met mutated NSCLC epidemiology report and model were written and developed by Masters and PhD level epidemiologists
- The C-Met mutated NSCLC Epidemiology Model is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Topics Covered:
1. Key Insights
2. Executive Summary of C-Met NSCLC Epidemiology
3. C-Met Non-small Cell Lung Cancer (NSCLC): Disease Background and Overview
3.1.1. Cellular Classification of NSCLC
3.1.2. Signs and Symptoms of NSCLC
3.1.3. Risk Factors of Lung Cancer
3.1.4. Causes of NSCLC
3.1.5. Disease Biology: NSCLC
4. Diagnosis of NSCLC
4.1. Diagnostic Algorithm for NSCLC
4.2. Stages of NSCLC
4.3. Staging System
5. Epidemiology and Patient Population
5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
5.3.1. Total Incident cases of NSCLC patients in the 7MM
5.3.2. Total Incident cases of NSCLC patients by Histology in the 7MM
5.3.3. Total Diagnosed cases of NSCLC patients by Stages in the 7MM
5.4. The United States Epidemiology
5.4.1. Total Incident cases of NSCLC patients in the United States
5.4.2. Total Incident cases of NSCLC patients by Histology in the United States
5.4.3. Total Diagnosed cases of NSCLC patients by Stages in the United States
5.4.4. Total Incident cases of C-Met Mutated NSCLC in the United States
6. EU-5 Epidemiology
6.5. The United Kingdom
7. Japan Epidemiology
9. Report Methodology
10. Publisher Capabilities
12. About the Publisher
For more information about this report visit https://www.researchandmarkets.com/r/t7o1vn